Noveome is a clinical-stage biopharmaceutical company focused on next-generation biologics to promote and restore cellular integrity of inflamed or damaged tissues. Its multi-target platform biologic and lead product, ST266, is a complex, non-cellular product containing hundreds of biologically active proteins and other biologic factors. ST266 is being evaluated across CNS, ophthalmic, pulmonary, and gastrointestinal indications, with an ongoing Phase 1 intranasal trial and an ongoing Phase 2 trial in corneal defects; topline data and several preclinical results were expected later in 2019. Proceeds from the financing will support advancement of the company’s clinical-stage ophthalmological and CNS programs and the broader pipeline of indications. The company has received seed funding from Lancet Capital and substantial non-dilutive research and infrastructure funding (including over $120 million from the U.S. Department of Defense, the Commonwealth of Pennsylvania, and Allegheny County) and had raised $144 million prior to this Series D. Noveome is based in Pittsburgh, PA.

Total raised

$15M

Funding rounds

1

Latest round

Series D

Latest activity

Apr 2019